Substance / Medication

Laronidase

Overview

Active Ingredient
laronidase
RxNorm CUI
392509

Indications

® ALDURAZYMEis indicated for the treatment of: adult and pediatric patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and patients with the Scheie form of MPS I who have moderate to severe symptoms.

Labeler: Genzyme CorporationUpdated: 2023-12-22T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Enzyme replacement therapy with laronidase (Aldurazyme) for treating mucopolysaccharidosis type I.
Jameson Elisabeth, Jones Simon, Remmington Tracey · Cochrane Database Syst Rev · 2019
PMID: 31211405Meta-AnalysisFull text (PMC)
Efficacy of laronidase therapy in patients with mucopolysaccharidosis type I who initiated enzyme replacement therapy in adult age. A systematic review and meta-analysis.
Pérez-López Jordi, Morales-Conejo Montserrat, López-Rodríguez Mónica et al. · Mol Genet Metab · 2017
PMID: 28410878Meta-Analysis
Efficacy and safety of intravenous laronidase for mucopolysaccharidosis type I: A systematic review and meta-analysis.
Dornelles Alícia Dorneles, Artigalás Osvaldo, da Silva André Anjos et al. · PLoS One · 2017
PMID: 28859139Meta-AnalysisFull text (PMC)
Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.
Jameson Elisabeth, Jones Simon, Remmington Tracey · Cochrane Database Syst Rev · 2016
PMID: 27033167Meta-Analysis
Enzyme replacement therapy with laronidase (Aldurazyme) for treating mucopolysaccharidosis type I.
Jameson Elisabeth, Jones Simon, Wraith James E · Cochrane Database Syst Rev · 2013
PMID: 24085657Meta-Analysis
Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.
Jameson Elisabeth, Jones Simon, Wraith James E · Cochrane Database Syst Rev · 2013
PMID: 24257962Meta-Analysis
Laronidase for treating mucopolysaccharidosis type I.
El Dib R P, Pastores G M · Genet Mol Res · 2007
PMID: 18050087Meta-Analysis
Alternative laronidase dose regimen for patients with mucopolysaccharidosis I: a multinational, retrospective, chart review case series.
Horovitz Dafne Dain Gandelman, Acosta Angelina X, Giugliani Roberto et al. · Orphanet J Rare Dis · 2016
PMID: 27129473ObservationalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Laronidase (substance)
SNOMED CT
409264006
UMLS CUI
C1302054
RxNorm CUI
392509
Labeler
Genzyme Corporation

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.